-- Insmed Leads Science Top Employers
List for Third Consecutive Year --
BRIDGEWATER, N.J., Oct. 26,
2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:
INSM), a global biopharmaceutical company on a mission to transform
the lives of patients with serious and rare diseases, today
announced that it has earned the highest ranking in
Science's 2023 Top Employers Survey. The annual survey polls
employees in biotechnology, pharmaceutical, and related industries
to determine the 20 best employers, as well as their driving
characteristics.
"I am immensely proud to have been ranked the No. 1 employer in
Science's annual survey for the third year in a
row—something that only Genentech and Regeneron have achieved in
the list's more than 20-year history," said Will Lewis, Chair and Chief Executive Officer of
Insmed. "At Insmed, we know that our people are our most valuable
asset, and it is because of them that we have received this honor
once again. I would like to thank our colleagues around the world
for their commitment to one another, the pursuit of groundbreaking
science, the patients we serve, and the communities around us."
The 2023 survey results were based on more than 6,800 responses
from individuals across North
America (59%), Europe
(18%), Asia/Pacific Rim (16%), and
other locations (7%). This year's highest-ranking companies stood
out in the areas of innovative leadership, respect for employees,
social responsibility, values alignment, and employee loyalty.
Following Insmed, the top five companies in 2023 included Incyte,
Alnylam, Regeneron, and Syngenta Group.
"Receiving the title of Top Biopharma Employer once again is an
incredible honor and a testament to the unique and special culture
that we have built," said Nicole
Schaeffer, Chief People Strategy Officer of Insmed. "Our
organization has always put our people, the science, and the
patients we serve at the forefront. As we approach an exciting year
and prepare for continued growth ahead, it is inspiring to witness
our employees' commitment to not only upholding our culture, but
also continuing to strengthen and enrich it as our company
evolves."
The complete feature and company rankings can be accessed here.
To learn more about Insmed's culture and explore opportunities
to join our team, please visit
https://insmed.com/culture/careers/.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a
mission to transform the lives of patients with serious and rare
diseases. Insmed's first commercial product is a first-in-disease
therapy approved in the United
States, Europe, and
Japan to treat a chronic,
debilitating lung disease. The Company is progressing a robust
pipeline of investigational therapies targeting areas of serious
unmet need, including neutrophil-mediated inflammatory diseases and
rare pulmonary disorders. Insmed is also advancing an early-stage
research engine encompassing a wide range of technologies and
modalities, including artificial intelligence-driven protein
engineering, gene therapy, and protein manufacturing. Insmed is
headquartered in Bridgewater, New
Jersey, with additional offices and research locations
throughout the United States,
Europe, and Japan. Visit www.insmed.com to learn more.
Contact:
Investors:
Bryan Dunn
Executive Director, Investor Relations
Insmed
(646) 812-4030
bryan.dunn@insmed.com
Eleanor Barisser
Associate Director, Investor Relations
Insmed
(718) 594-5332
eleanor.barisser@insmed.com
Media:
Mandy Fahey
Executive Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/insmed-ranks-no-1-on-sciences-2023-top-biopharma-employers-list-301969284.html
SOURCE Insmed Incorporated